What does ecc stand for in gynecology

Hereditary cancers in gynecology

CME questionnaire

A 45 year old seeking advice with pathogenic BRCA1-Mutation comes to you in the consultation hour and asks about possible additional risk factors for breast cancer. Which factor is Not potentially risk-modifying in familial breast and ovarian cancer?

Birth cohort

BMI (body mass index)

Use of contraceptives

Physical activity

Stepmother's breast cancer

Radiation of the breast should be used for which genetic modification Not be performed?

BRCA1

RAD51C

TP53

PALB2

CDH1

Who should be the first in a family to be tested for molecular genetic testing in familial breast and ovarian cancer?

The oldest sick person in the family

Women with ovarian cancer

The youngest sick person in the family

Always the daughter of someone who is sick

Always the father of the person seeking advice

What is a PARP ("poly ADP [adenosine diphosphate] ribose polymerase") inhibitor therapy currently for, among other things? authorized?

For HER2-positive metastatic breast cancer

In cervical cancer

In triple-negative metastatic breast cancer with mutation in BRCA1 or BRCA2 in tumor tissue

In hormone receptor-positive metastatic breast cancer with mutation in BRCA1 or BRCA2 in the germline

For uterine sarcomas

What does predictive testing mean in connection with hereditary cancers?

Testing a sick person

Follow-up testing of other sick people if a pathogenic mutation in the family is detected

Testing on tumor tissue

Testing of males only

Testing of a healthy person with a proven pathogenic mutation in the family

Which statement on drug tumor therapy is correct?

PARP ("poly ADP [adenosine diphosphate] ribose polymerase") inhibitors are used in the therapy of relapsed ovarian cancer with response to a therapy containing platinum.

In metastatic breast cancer patients with hormone-receptor-positive tumors and pathogenic ones BRCA2-Mutation, CDK ("cyclin-dependent kinase") 4/6 inhibitors have no effect.

PARP inhibitors are also used in endometrial cancer.

The BRCA-The mutation status has no informative value on the therapeutic response of a PARP inhibitor.

Somatic mutations in ovarian cancer are generally negligible.

Which statement on the intensified early detection of familial breast and ovarian cancer is correct?

Mammography is integrated from the age of 25.

A breast MRI (magnetic resonance imaging) examination is recommended up to the age of 40.

The ultrasound has no place in the intensified early diagnosis.

A breast MRI examination should be carried out annually.

For early detection of ovarian cancer, a pelvic MRI should be performed every 2 years.

After the 45-year-old patient with pathogenic BRCA1-Mutation asked you about other possible risk factors for breast cancer, she would now like to find out more about surgical risk-reducing measures. Which statement about risk-reducing operations is correct?

In a bilateral salpingo-ovariectomy due to a BRCA-Mutation, the hysterectomy must always be performed.

Hysterectomy in Lynch syndrome can be described as a risk-reducing intervention.

A bilateral mastectomy at BRCA-Mutations should not take place before the age of 50.

Competing risks do not play a role in the indication for surgical interventions.

A breast cancer when proven BRCA-Mutation always requires a mastectomy.

Which statement about Lynch syndrome is correct?

A colonoscopy from the age of 25 is recommended annually.

It only affects thyroid cancer.

A risk-reducing removal of the colon should be discussed with the patient.

After the age of 50, there is no longer any risk of endometrial cancer.

A risk-reducing irradiation of the pelvis after the end of the desire to have children is indicated.

Which statement is about germline mutations not correct?

With an autosomal inheritance, men can also be carriers of a mutation.

The risk for a girl of having a germline mutation from her father with pathogenic BRCA1- Inheriting mutation is 50%.

Germline mutations can only be found in tumor tissue.

Germline mutations with regard to hereditary cancers usually have incomplete penetrance.

Germline mutations are rather rare.